Journal:IUCrJ:S205225251901707X

From Proteopedia

(Difference between revisions)
Jump to: navigation, search
Current revision (13:09, 21 June 2022) (edit) (undo)
 
(25 intermediate revisions not shown.)
Line 1: Line 1:
-
<StructureSection load='' size='450' side='right' scene='underdevelopment' caption=''>
+
<StructureSection load='' size='450' side='right' scene='83/832917/Cv/1' caption=''>
-
===Structural insights into conformational switching in latency-associated peptide between TGF[beta]-1 bound and unbound states===
+
===Structural insights into conformational switching in latency-associated peptide between TGFβ-1 bound and unbound states===
<big>Timothy R. Stachowski, Mary E. Snell, and Edward H. Snell</big> <ref>doi 10.1107/S205225251901707X</ref>
<big>Timothy R. Stachowski, Mary E. Snell, and Edward H. Snell</big> <ref>doi 10.1107/S205225251901707X</ref>
<hr/>
<hr/>
<b>Molecular Tour</b><br>
<b>Molecular Tour</b><br>
-
In response to environmental changes, proteins are released from cells that act as messengers, which allows cells to communicate with one another and coordinate a physiologic response. Transforming growth factor beta-1 (TGFb-1) is a protein used to communicate information about when and how cells should proliferate and is particularly important in organizing embryonic tissue development. The fundamental way our cells regulate TGFb-1 activity is with a second protein, latency-associated peptide (LAP). LAP forms a complex with TGFb-1, tethering it to the outside surface of the cell. Several pathologies including cancer progression and immune suppression are driven by an overabundance of TGFb-1.
+
In response to environmental changes, proteins are released from cells that act as messengers, which allows cells to communicate with one another and coordinate a physiologic response. Transforming growth factor β-1 (TGFβ-1) is a protein used to communicate information about when and how cells should proliferate and is particularly important in organizing embryonic tissue development. The fundamental way our cells regulate TGFβ-1 activity is with a second protein, latency-associated peptide (LAP). LAP forms a complex with TGFβ-1, tethering it to the outside surface of the cell. Several pathologies including cancer progression and immune suppression are driven by an overabundance of TGFβ-1.
-
Because LAP binding reduces TGFb-1 activity, recombinant LAP is a promising novel therapeutic approach, however a detailed understanding of how LAP binds TGFb-1 is missing, which could reveal ways to improve the LAP-TGFb-1 interaction or develop other anti-TGFb-1 therapies. In a paper in IUCrJ, Stachowski et al. show that LAP adopts structurally distinct conformations between unbound and TGFb-1 bound states. This was revealed by comparing the X-ray crystal structure of LAP in the unbound state solved by Stachowski et al. with the crystal structure of LAP bound to TGFb-1 previously reported by Shi et al. 2011. This analysis combined with solution modelling showed that LAP transitions from an extended to compact conformation when binding TGFb-1, simulating a type of hugging motion where LAP embraces TGFb-1. Surprisingly, this conformational change includes rearranging two domains that are distant from one another and might be coordinated through the formation of an a-helix that is distant from the LAP-TGFb-1 interaction site. Together, these results provide new spatial details about the TGFb-1 binding mechanism, specifically how LAP reorients itself to develop the LAP-TGFb-1 interface. This insight is important as it provides new avenues to engineer and improve LAP as a therapeutic that are focused beyond just the interaction site.
+
Because LAP binding reduces TGFβ-1 activity, recombinant LAP is a promising novel therapeutic approach, however a detailed understanding of how LAP binds TGFβ-1 is missing, which could reveal ways to improve the LAP-TGFβ-1 interaction or develop other anti-TGFβ-1 therapies. In a paper in IUCrJ, ''Stachowski et al.'' show that LAP adopts structurally distinct conformations between unbound and TGFβ-1 bound states. This was revealed by comparing the X-ray crystal structure of LAP in the unbound state ([[6p7j]]) solved by ''Stachowski et al.'' with the crystal structure of LAP bound to TGFβ-1 ([[3rjr]]) previously reported by ''Shi et al.'' 2011 <ref name="Shi">PMID:21677751</ref>. This analysis combined with solution modelling showed that LAP transitions from an extended to compact conformation when binding TGFβ-1, simulating a type of hugging motion where LAP embraces TGFβ-1. Surprisingly, this conformational change includes rearranging two domains that are distant from one another and might be coordinated through the formation of an α-helix that is distant from the LAP-TGFβ-1 interaction site. Together, these results provide new spatial details about the TGFβ-1 binding mechanism, specifically how LAP reorients itself to develop the LAP-TGFβ-1 interface. This insight is important as it provides new avenues to engineer and improve LAP as a therapeutic that are focused beyond just the interaction site.
 +
 
 +
Comparison of apo LAP and TGFβ-1 (LTGFβ-1) bound structures. Only residues modelled in the apo structure were included for comparison. The apo structure reported here (royalblue; PDB entry [[6p7j]]) is aligned with pig TGFβ-1 bound LAP (yellow; PDB entry [[3rjr]], ''Shi et al., 2011''<ref name="Shi">PMID:21677751</ref>):
 +
*<scene name='83/832917/Cv/7'>Side view shows the inter-monomer angle in the apo structure is 15˚ greater than in the bound structure</scene>. The angle measured here reflects the shift of one monomer in the bound structure relative to the same monomer in the apo structure. <scene name='83/832917/Cv/15'>Click here to see morph</scene>. <jmol><jmolButton>
 +
<script>if (_animating); anim pause;set echo bottom left; color echo white; font echo 20 sansserif;echo Animation Paused; else; anim resume; set echo off;endif;</script>
 +
<text>Please click here to pause animation before next scene</text>
 +
</jmolButton></jmol>
 +
*<scene name='83/832917/Cv/10'>Front orientation of the alignment</scene>. RGD indicates the integrin binding motif. <scene name='83/832917/Cv/17'>Click here to see morph</scene>. <jmol><jmolButton>
 +
<script>if (_animating); anim pause;set echo bottom left; color echo white; font echo 20 sansserif;echo Animation Paused; else; anim resume; set echo off;endif;</script>
 +
<text>Please click here to pause animation before next scene</text>
 +
</jmolButton></jmol>
 +
*<scene name='83/832917/Cv/8'>A close-up view of the RGD containing loop</scene> shows that it is similarly positioned in both structures, on the solvent exposed shoulder of the arm domain. For clarity, the Cα atoms of G and D (which are modelled in both structures) from the motif are shown as spheres. <scene name='83/832917/Cv/19'>Click here to see morph</scene>. <jmol><jmolButton>
 +
<script>if (_animating); anim pause;set echo bottom left; color echo white; font echo 20 sansserif;echo Animation Paused; else; anim resume; set echo off;endif;</script>
 +
<text>Pause/Start Animation</text>
 +
</jmolButton></jmol>
 +
 
 +
'''PDB reference:''' latency-associated peptide, [[6p7j]].
<b>References</b><br>
<b>References</b><br>

Current revision

Drag the structure with the mouse to rotate

Proteopedia Page Contributors and Editors (what is this?)

Alexander Berchansky, Jaime Prilusky

This page complements a publication in scientific journals and is one of the Proteopedia's Interactive 3D Complement pages. For aditional details please see I3DC.
Personal tools